



December 21, 2022

BSE Limited

Department of Corporate Services,
P. J. Towers,
Dalal Street,
MUMBAI - 400 001.

✓ **National Stock Exchange of India Limited**

Exchange Plaza,
Bandra Kurla Complex,
Bandra (East),
Mumbai - 400 051.

Dear Sir/Madam,

Sub: Disclosure pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations).

We are pleased to enclose a Press Release as regards, receipt of U.S. FDA approval for the Company's Abbreviated New Drug Application for Brivaracetam Tablets, 10 mg, 25 mg, 50 mg, 75 mg, and 100 mg, a generic equivalent of Briviact® Tablets, 10 mg, 25 mg, 50 mg, 75 mg, and 100 mg, of UCB Inc.

This may kindly be considered as a disclosure pursuant to Regulation 30 of the Listing Regulations.

The above is for your information and dissemination.

Thanking you,

For LUPIN LIMITED

**Rajvardhan
Vishnu Satam**

**R. V. SATAM
COMPANY SECRETARY
(ACS - 11973)**

Digitally signed by Rajvardhan Vishnu Satam
DN: c=IN, st=Maharashtra,
2.5.4.20=c19d8e9961d9fa59e973a093a4d3924b2532eb2f496ea7e
2abc74700f5375b7, postalCode=400104, street=2404, SEJAL
TOWER, SEJAL PARK, LINK ROAD, GOREGAON
WEST, Mumbai, Motilal Nagar, Borivali, Mumbai Suburban,
pseudonym=9a4b7cd219ea516ad56e6d551dcbbe9b, title=0191,
serialNumber=d8beb60a8c796663c738ea25fa0d475d195f726
c0b67a2ff09c4242771b2a, o=Personal, cn=Rajvardhan Vishnu
Satam
Date: 2022.12.21 12:30:03 +05'30'

Encl: a/a

Lupin Receives Approval from U.S. FDA for Brivaracetam Tablets

Mumbai, Baltimore, December 21, 2022: Global pharma major Lupin Limited (Lupin) today announced that it has received approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application (ANDA) for Brivaracetam Tablets, 10 mg, 25 mg, 50 mg, 75 mg, and 100 mg, a generic equivalent of Briviact® Tablets, 10 mg, 25 mg, 50 mg, 75 mg, and 100 mg, of UCB Inc. The product will be manufactured at Lupin's facility in Nagpur, India.

Brivaracetam Tablets, 10 mg, 25 mg, 50 mg, 75 mg, and 100 mg, (RLD Briviact®) had estimated annual sales of USD 420 million in the U.S. (IQVIA MAT September 2022).

About Lupin

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.

The Company enjoys a leadership position in the cardiovascular, anti-diabetic, and respiratory segments and has a significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS), and women's health areas. Lupin is the third-largest pharmaceutical company in the U.S. by prescriptions. The company invested 8.7% of its revenue in research and development in FY22.

Lupin has 15 manufacturing sites, 7 research centers, more than 20,000 professionals working globally, and has been consistently recognized as a 'Great Place to Work' in the Biotechnology & Pharmaceuticals sector.

Please visit www.lupin.com for more information.

Follow us on Twitter: <https://twitter.com/LupinGlobal> | LinkedIn: <https://www.linkedin.com/company/lupin>

Facebook: <http://www.facebook.com/LupinWorld/>

For further information or queries please contact –

Shweta Munjal

Vice President & Global Head – Corporate Communications

Email: shwetamunjal@lupin.com

***Safe Harbor Statement**

Briviact® is a registered trademark of UCB Biopharma SRL.